A Phase 3 interventional study of Epoetin Hospira Arm and Standard of Care Arm in Chronic Kidney Disease (CKD), sponsored by Pfizer. Completed at 45 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-13.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 3, and was the 22nd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2015.
This study's enrollment of 432 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 157 across the 25 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Epoetin Alfa in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
Primary Objective: To evaluate switching from Epogen to Epoetin Hospira for maintenance of hemoglobin levels in anemic chronic kidney disease (CKD) subjects on hemodialysis using a specified algorithm for the dosing of erythropoietin stimulating agents (ESA).
Secondary Objective: To evaluate switching from Epogen to Epoetin Hospira on the dosing of ESA in anemic CKD subjects on hemodialysis using a specified algorithm for the dosing of ESA.
Exploratory Objectives: To generate hypotheses regarding maintenance of hemoglobin levels, dosing of ESA, intravenous (IV) iron dosing requirements, transferrin saturation (TSAT) levels and ferritin levels associated with the switch from Epogen to Epoetin Hospira in anemic CKD subjects on hemodialysis using specified algorithms for the dosing of ESA and for the dosing of IV iron, that are standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible to be entered into the study will meet all of the following criteria:
Exclusion Criteria
Subjects that meet any of the following criteria will be ineligible to be entered into the interventional cohort:
Diagnosed with any concurrent condition that could lead to greater-than-normal loss of blood, including but not limited to:
Subjects started on warfarin with a known INR goal of 2.0 or greater are to receive no further treatment with the study drugs, but follow up visits can continue.
Subjects on warfarin who meet criteria to enter the study are terminated if an INR > 2.0 is discovered or if no INR is available for 60 days.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin Hospira Arm
Biological: Epoetin Hospira Arm · Drug: IV Iron
Standard of care arm
Other: Standard of Care Arm · Drug: IV Iron
Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)
Time frame: Week 17 up to Week 24
Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment
Time frame: Baseline (8 Weeks prior to randomization), Week 17 up to Week 24
| Milestone | Epoetin Hospira | Epogen |
|---|---|---|
| Started | 212 | 206 |
| Completed | 156 | 158 |
| Not completed | 56 | 48 |
| Withdrew: Adverse event | 15 | 12 |
| Withdrew: Withdrawal by subject | 7 | 1 |
| Withdrew: Protocol violation | 27 | 26 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Lost to follow-up | 6 | 7 |
| Percentage of Weeks | Epoetin Hospira | Epogen |
|---|---|---|
| Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL) | 61.9330 (57.5106 to 66.1659) | 63.3305 (58.7061 to 67.7217) |
| Units per week | Epoetin Hospira | Epogen |
|---|---|---|
| Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment | -1861.8 ± 563.50 | -799.8 ± 573.14 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Hospira | — | 66/212 (31.1%) | 10/212 (4.7%) |
| Epogen | — | 64/206 (31.1%) | 21/206 (10.2%) |
| Event | Epoetin Hospira | Epogen |
|---|---|---|
| PneumoniaInfections and infestations | 7/212 | 1/206 |
| Cardiac arrestCardiac disorders | 2/212 | 6/206 |
| HyperkalaemiaMetabolism and nutrition disorders | 5/212 | 1/206 |
| Condition aggravatedGeneral disorders | 4/212 | 3/206 |
| Fluid overloadMetabolism and nutrition disorders | 4/212 | 3/206 |
| Cardiac failure congestiveCardiac disorders | 0/212 | 3/206 |
| Chest painGeneral disorders | 3/212 | 1/206 |
| SepsisInfections and infestations | 3/212 | 1/206 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/82 | 1/102 |
| AnaemiaBlood and lymphatic system disorders | 1/212 | 2/206 |
| Event | Epoetin Hospira | Epogen |
|---|---|---|
| NauseaGastrointestinal disorders | 3/212 | 13/206 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/212 | 11/206 |
Full analysis set (FAS) included all participants who received at least 1 dose of study medication after randomization into the study.
| Age, Continuous(Years) | Epoetin Hospira | Epogen | Total |
|---|---|---|---|
| Mean | 60.5 ± 13.96 | 59.3 ± 14.23 | 59.9 ± 14.09 |
| Sex: Female, Male(Participants) | Epoetin Hospira | Epogen | Total |
|---|---|---|---|
| Female | 82 | 102 | 184 |
| Male | 130 | 104 | 234 |
Ran from Jul 2015 to primary completion in Jul 2016, 11 months.
Results were first posted in Jun 2018, 1 year 11 months after primary completion. A results delay was requested in Sep 2017.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 11 months is below that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Renal Insufficiency, Chronic →